Targeting Hypoxia-Inducible Factor-1 (HIF-1) in Cancer: Emerging Therapeutic Strategies and Pathway Regulation
Pharmaceuticals · 01.02.2024 · 17 (2) · 195
DOI: 10.3390/ph17020195 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 01.02.2024. Verfasst von Reem A Qannita und 11 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute of Medical and Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates. Die Arbeit wurde bisher 131-mal zitiert (Crossref) und nennt 137 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hypoxia-inducible factor-1 (HIF-1) is a key regulator for balancing oxygen in the cells. It is a transcription factor that regulates the expression of target genes involved in oxygen homeostasis in response to hypoxia. Recently, research has demonstrated the multiple roles of HIF-1 in the pathophysiology of various diseases, including cancer. It is a crucial mediator of the hypoxic response and regulator of oxygen metabolism, thus contributing to tumor development and progression. Studies showed that the expression of the HIF-1α subunit is significantly upregulated in cancer cells and promotes tumor survival by multiple mechanisms. In addition, HIF-1 has potential contributing roles in cancer progression, including cell division, survival, proliferation, angiogenesis, and metastasis. Moreover, HIF-1 has a role in regulating cellular metabolic pathways, particularly the anaerobic metabolism of glucose. Given its significant and potential roles in cancer development and progression, it has been an intriguing therapeutic target for cancer research. Several compounds targeting HIF-1-associated processes are now being used to treat different types of cancer. This review outlines emerging therapeutic strategies that target HIF-1 as well as the relevance and regulation of the HIF-1 pathways in cancer. Moreover, it addresses the employment of nanotechnology in developing these promising strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Research Institute of Medical and Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates.
- College of Medicine, University of Sharjah, Sharjah 27272, United Arab Emirates.
- Department of Basic Sciences, Faculty of Arts and Sciences, Al-Ahliyya Amman University, Amman 19111, Jordan.
- School of Pharmacy, The University of Jordan, Amman 11942, Jordan.
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.
- Department of Pharmacy Practice and Pharmacotherapeutics, College of Pharmacy, University of Sharjah, Sharjah 27272, United Arab Emirates.
ORCID-Profile: Shereen M Aleidi, Jalal Taneera, Eman Abu-Gharbieh, Waseem El-Huneidi, Mohamed A Saleh, Mohammad H Semreen, Mohammad Hudaib, Yasser Bustanji
Zitieren
APA
Qannita, R. A., Alalami, A. I., Harb, A. A., Aleidi, S. M., Taneera, J., Abu-Gharbieh, E., El-Huneidi, W., Saleh, M. A., Alzoubi, K. H., Semreen, M. H., Hudaib, M., & Bustanji, Y. (2024). Targeting Hypoxia-Inducible Factor-1 (HIF-1) in Cancer: Emerging Therapeutic Strategies and Pathway Regulation. Pharmaceuticals, 17(2), 195. https://doi.org/10.3390/ph17020195
Vancouver
Qannita RA, Alalami AI, Harb AA, Aleidi SM, Taneera J, Abu-Gharbieh E, et al. Targeting Hypoxia-Inducible Factor-1 (HIF-1) in Cancer: Emerging Therapeutic Strategies and Pathway Regulation. Pharmaceuticals. 2024;17(2):195. doi:10.3390/ph17020195
BibTeX
@article{Qannita2024,
author = {Qannita, Reem A and Alalami, Ayah I and Harb, Amani A and Aleidi, Shereen M and Taneera, Jalal and Abu-Gharbieh, Eman and El-Huneidi, Waseem and Saleh, Mohamed A and Alzoubi, Karem H and Semreen, Mohammad H and Hudaib, Mohammad and Bustanji, Yasser},
title = {Targeting Hypoxia-Inducible Factor-1 (HIF-1) in Cancer: Emerging Therapeutic Strategies and Pathway Regulation},
journal = {Pharmaceuticals},
year = {2024},
volume = {17},
number = {2},
pages = {195},
doi = {10.3390/ph17020195}
}
EUVIMED